EXHIBIT 11

```
UNITED STATES DISTRICT COURT
 1
 2
           FOR THE NORTHERN DISTRICT OF OHIO
 3
                    EASTERN DIVISION
 4
 5
    IN RE: NATIONAL
    PRESCRIPTION
                                : MDL No. 2804
 6
    OPIATE LITIGATION
                                : Case No.
                                  1:17-MD-2804
    THIS DOCUMENT RELATES
    TO ALL CASES
                            : Hon. Dan A. Polster
 9
               Thursday, December 6, 2018
10
11
        HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
                 CONFIDENTIALITY REVIEW
12
13
14
            Videotaped deposition of JASON BRISCOE, held
    at the offices of Cavitch, Familo & Durkin,
15
    1300 East Ninth Street, Cleveland, Ohio, commencing at
16
17
    9:05 a.m., on the above date, before Carol A. Kirk,
    Registered Merit Reporter and Notary Public.
18
19
20
21
22
               GOLKOW LITIGATION SERVICES
           877.370.3377 ph | 917.591.5672 fax
23
                    deps@golkow.com
2.4
```

- on behalf of DDM regarding its duties under
- federal law as a distributor, correct?
- 3 A. Yes.
- 4 Q. And you understand, sir, today
- 5 that DDM is here in its capacity as a
- 6 distributor to its own wholly-owned pharmacies,
- 7 correct?
- 8 A. Yes.
- 9 Q. And you understand that its role
- 10 as a distributor is different than its role and
- 11 obligation as a pharmacy or dispensing
- 12 operation, correct?
- 13 A. Yes.
- Q. Under d, "Your past/present
- interpretation, compliance, agreement and/or
- 16 disagreement with the reporting requirement and
- shipping requirement as referenced in Masters
- 18 Pharmaceutical."
- 19 Are you familiar and prepared to
- testify today about the shipping requirement and
- 21 the due diligence requirement under -- I'm
- 22 sorry -- reporting requirement and shipping
- 23 requirement as reported and referenced in
- 24 Masters?

```
1301.74 --
 1
 2
             Α.
                 Okay.
                   -- titled "Other security controls
 3
             Q.
     for non-practitioners; narcotic treatment
 5
    programs and compounders for narcotic treatment
    programs."
 6
 7
                   And do you see under (b) -- well,
     let's do (a) first. (a), "Before distributing a
 8
 9
     controlled substance to any person who the
10
     registrant does not know to be registered to
11
    possess the controlled substance, the registrant
12
     shall make a good faith inquiry with the
    administration or with the appropriate State
13
14
     controlled substances registration agency, if
15
     any, to determine that person is registered to
16
    possess the controlled substance."
17
                   So for DDM, DDM only distributed
     to it's wholly-owned pharmacies, correct?
18
19
             Α.
                   Correct.
20
                   So under (b), sir, is it your
             Q.
21
    understanding that DDM was obligated to design
22
     and operate a system to disclose the registrant
23
     suspicious orders of controlled substances?
24
```

Α.

Yes.